Relay Therapeutics Inc (NASDAQ:RLAY) shares, rose in value on Thursday, March 06, with the stock price up by 2.65% to the previous day’s close as strong demand from buyers drove the stock to $3.48.
Actively observing the price movement in the last trading, the stock closed the session at $3.39. Referring to stock’s 52-week performance, its high was $10.72, and the low was $3.02. On the whole, RLAY has fluctuated by -24.84% over the past month.
With the market capitalization of Relay Therapeutics Inc currently standing at about $589.94 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.5k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RLAY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RLAY currently trading nearly -7.84% and -17.26% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.75, while the 7-day volatility ratio is showing 11.33% which for the 30-day chart, stands at 8.33%. Furthermore, Relay Therapeutics Inc (RLAY)’s beta value is 1.63, and its average true range (ATR) is 0.33.
A comparison of Relay Therapeutics Inc (RLAY) with its peers suggests the former has fared considerably weaker in the market. RLAY showed an intraday change of 2.65% in last session, and over the past year, it shrunk by -65.71%%.
Data on historical trading for Relay Therapeutics Inc (NASDAQ:RLAY) indicates that the trading volumes over the past 3 months, they’ve averaged 2.36 million. According to company’s latest data on outstanding shares, there are 167.76 million shares outstanding.
Nearly 24.99% of Relay Therapeutics Inc’s shares belong to company insiders and institutional investors own 75.25% of the company’s shares. The stock has fallen by -15.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RLAY stock heading into the next quarter.
